Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

A Study of the Effect of Concomitant Administration of Multiple Doses of BMS-708163 on the Pharmacokinetics of Galantamine in Healthy Subjects

The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.

Inclusion Criteria:

• Healthy men and postmenopausal women

Exclusion Criteria:

• Gastrointestinal disorders
• Bleeding disorders
• Peptic ulcer disease
• Cholecystectomy
• Seizure disorder
• Asthma
• Chronic obstructive pulmonary disease
• Urinary tract obstruction
• Cardiac conduction abnormalities, including but not limited to "sick sinus syndrome" and those with unexplained syncopal episodes
• Inability to tolerate oral medication
• Inability to be venipunctured and/or tolerate venous access